Skip to content
10-K

Annual Report

Atea Pharmaceuticals, Inc. AVIR

0001193125-26-094159

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 4, 2026 79.67M sh
Shares Diluted FY 2025 · Dec 31, 2025 81.5M sh
Shares Diluted FY 2025 · Dec 31, 2024 84.26M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $25.52M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$132.03M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$135.5M
Cash And Equivalents FY 2025 · Dec 31, 2025 $95.71M
Cash And Equivalents FY 2025 · Dec 31, 2024 $64.7M
Stockholders Equity FY 2025 · Dec 31, 2025 $275.43M
Stockholders Equity FY 2025 · Dec 31, 2024 $438.87M
Stockholders Equity FY 2025 · Dec 31, 2023 $555.19M
Current Liabilities FY 2025 · Dec 31, 2025 $39.78M
Current Liabilities FY 2025 · Dec 31, 2024 $18.6M
Total Liabilities FY 2025 · Dec 31, 2025 $39.78M
Total Liabilities FY 2025 · Dec 31, 2024 $25.8M
Current Assets FY 2025 · Dec 31, 2025 $310.99M
Current Assets FY 2025 · Dec 31, 2024 $462.36M
Total Assets FY 2025 · Dec 31, 2025 $315.22M
Total Assets FY 2025 · Dec 31, 2024 $464.67M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.94
Eps Diluted FY 2025 · Dec 31, 2024 −$2.00
Eps Basic FY 2025 · Dec 31, 2025 −$1.94
Eps Basic FY 2025 · Dec 31, 2024 −$2.00
Sga Expense FY 2025 · Dec 31, 2025 $32.86M
Sga Expense FY 2025 · Dec 31, 2024 $48.85M
Rd Expense FY 2025 · Dec 31, 2025 $148.02M
Rd Expense FY 2025 · Dec 31, 2024 $144.1M
Net Income FY 2025 · Dec 31, 2025 −$158.35M
Net Income FY 2025 · Dec 31, 2024 −$168.39M
Operating Income FY 2025 · Dec 31, 2025 −$180.89M
Operating Income FY 2025 · Dec 31, 2024 −$192.95M